Suspension of trading

Spexis AG Share Price Swiss Exchange

Stocks

POLN

CH0106213793

Pharmaceuticals

OTC Markets Traded
Delayed Swiss Exchange 16:36:37 19/03/2025 GMT 5-day change 1st Jan Change
0.0100 CHF -75.00% Intraday chart for Spexis AG -75.00% -84.62%
3 months-82.46%
6 months-77.58%
1 week-75.00%
3 months-82.46%
6 months-77.58%
Current year-84.62%
1 week 0.01
Extreme 0.01
0.04
1 month 0.01
Extreme 0.01
0.06
3 years 0.01
Extreme 0.01
1.35
5 years 0.01
Extreme 0.01
9.45
Manager TitleAgeSince
Chief Executive Officer 64 30/03/2022
Director of Finance/CFO - 31/07/2024
Director TitleAgeSince
Chairman 70 19/11/2019
Director/Board Member 65 31/05/2013
Director/Board Member 80 29/12/2021
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-75.00%-88.89%-99.22% 817K
+1.18%+1.21%+17.96%-12.13% 63.44B
-1.68%+1.02%+54.39%+223.94% 56.98B
+0.36%+39.60%+39.60%+39.60% 41.58B
+3.16%+5.65%-50.57%-57.33% 38.01B
-1.39%+6.89%+64.02%-25.26% 31.9B
+3.81%+20.54%+153.85%-40.17% 27.79B
+0.24%+5.04%+65.76%+83.52% 22.65B
-0.56%+4.05%+1.53%+168.92% 17.64B
+0.84%-1.15%+63.32%+123.73% 16.49B
Average +0.71%+5.13%+32.10%+40.56% 35.16B
Weighted average by Cap. +0.61%+4.50%+40.57%+51.97%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B